Print Page  Close Window

Investor Center Home
Corporate Profile
Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders.

More >>

BLCM (Common Stock)
(US Dollar)
Change Stock is Down 0.08
(%)Volume (0.64%)670,098
Data as of 03/30/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
03/30/17Bellicum Pharmaceuticals Announces Closing of Public OfferingPrinter Friendly Version
03/23/17Bellicum Pharmaceuticals Announces Pricing of Public Offering of Common StockPrinter Friendly Version
03/22/17Bellicum Pharmaceuticals Announces Proposed Public Offering of Common StockPrinter Friendly Version
03/13/17Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016Printer Friendly Version
More >>
Upcoming Events
There are currently no events scheduled.
Past Events
03/15/17 4:20 p.m. ET
Bellicum Pharmaceuticals Inc at Barclays Global Healthcare Conference
Click here for webcast
03/13/17 5:00 p.m. ET
Q4 YE 2016 Bellicum Pharmaceuticals Earnings Conference Call
Click here for webcast
More >>
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources